Krka DDFRA:KN8 -3.02%66 PEG Ratio is 4.33 as of Jul. 13, 2026, which is 280% above its 10-year median of 1.14. GuruFocus rates FRA:KN8 with a GF Score™ of 66/100 and a GF Value™ of €148.68 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 348 Drug Manufacturers companies, Krka DD ranks worse than 77.3% on this metric.
PE Ratio without NRI / 5-Year EBITDA Growth Rate*
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Krka DD's PE Ratio without NRI is 21.64. Krka DD's 5-Year EBITDA growth rate is 5.00%. Therefore, Krka DD's PEG Ratio for today is 4.33.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Krka DD's PEG Ratio or its related term are showing as below:
FRA:KN8'
s PEG Ratio Range Over the Past 10 Years
Min: 0.44 Med: 1.14 Max: 8.57
Current: 4.39
During the past 13 years, Krka DD's highest PEG Ratio was 8.57. The lowest was 0.44. And the median was 1.14.
FRA:KN8's PEG Ratio is ranked worse than 77.3% of 348
companies
in the Drug Manufacturers industry
Industry Median: 1.665
vs FRA:KN8: 4.39
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Krka DD (FRA:KN8) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Krka DD PEG Ratio Related Terms
Krka DD PEG Ratio Historical Data
* Premium members only.
The historical data trend for Krka DD's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Krka DD's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krka DD PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Krka DD's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Krka DD's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Krka DD (FRA:KN8) has a PEG Ratio of 4.33 as of Jul. 13, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Krka DD and its competitors. This is 280% above median its historical median of 1.14. Over the past decade, Krka DD's PEG Ratio has ranged from 0.44 to 8.57. According to the industry distribution chart, Krka DD ranks #269 out of 348 companies in the Drug Manufacturers industry, placing it in the top 77.3%.
Is Krka DD's PEG Ratio too high?
Krka DD's current PEG Ratio of 4.33 is 280% above median its 10-year median of 1.14. Over the past 10 years, this metric has ranged from a low of 0.44 to a high of 8.57. The Drug Manufacturers industry median PEG Ratio is 1.67. Krka DD's value of 4.33 is 160.1% above this industry median. Based on the distribution chart, Krka DD ranks #269 out of 348 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Krka DD has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krka DD's PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Krka DD ranks #269 out of 348 companies for PEG Ratio. This places Krka DD in the lower half of its industry. The industry median PEG Ratio is 1.67. Krka DD's value of 4.33 is 160.1% above this benchmark. Historically, Krka DD's own PEG Ratio has ranged from 0.44 to 8.57 over the past decade. While the company's 10-year median is 1.14 vs. the industry median of 1.67, Krka DD has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.67, based on 348 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krka DD's current PEG Ratio of 4.33 is 160.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Krka DD and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krka DD's current PEG Ratio is 4.33, which is 280% above median its own 10-year median of 1.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krka DD stock overvalued right now?
Based on GuruFocus' analysis, Krka DD (FRA:KN8) is currently considered Significantly Overvalued. The stock's GF Value™ is €148.68, compared to a current price of €257.00 — trading 72.9% above its estimated fair value. The current PEG Ratio is 4.33, which is 280% above median its 10-year median of 1.14 and 160.1% above the Drug Manufacturers industry median of 1.67. Krka DD's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Krka DD (FRA:KN8), the current PEG Ratio is 4.33 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krka DD (FRA:KN8) Overvalued in 2026?
Based on GuruFocus' analysis, Krka DD stock appears to be overvalued.
The current stock price of €257.00 is trading 72.9% above its estimated GF Value™ of €148.68.
GuruFocus considers Krka DD to be Significantly Overvalued.
Key valuation signals for FRA:KN8:
PEG Ratio: 4.33 (280% above median its 10-year median of 1.14)
GF Value™: €148.68 vs. price of €257.00 (72.9% above fair value)
Industry Position: 160.1% above the Drug Manufacturers median (#269 of 348)
No single metric tells the full story. See the FRA:KN8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krka DD engages in the development, production, marketing, and sales of human health products (prescription pharmaceuticals and non-prescription products), animal health products, health resorts, and tourist services. The company's products in Prescription pharmaceuticals include Cardiovascular diseases, Infections, and Oncology; Non-prescription products include Cold and cough products, nasal products, vitamins and minerals, and hair care products; and Animal health products include Antimicrobials and disinfectants, among others. It operates across the European Union, South-East Europe, Eastern Europe region, and Others. The company derives a majority of its revenue from the European Union.
66GF Score
Get the complete analysis for FRA:KN8
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:KN8 has been successfully added to your 
